Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200217, China.
Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Drug Discov Today. 2022 Jun;27(6):1622-1638. doi: 10.1016/j.drudis.2022.03.013. Epub 2022 Mar 21.
In recent years, nanobodies have emerged as ideal imaging agents for molecular imaging. Molecular nanobody imaging combines the specificity of nanobodies with the sensitivity of state-of-the-art molecular imaging modalities, such as positron emission tomography (PET). Given that modifications of nanobodies alter their pharmacokinetics (PK), the engineering strategies that combine nanobodies with radionuclides determine the effectiveness, reliability, and safety of the molecular imaging probes. In this review, we introduce conjugation strategies that have been applied to engineer nanobodies, including random conjugation, Tc tricarbonyl chemistry, sortase A-mediated site-specific conjugation, maleimide-cysteine chemistry, and click chemistries. We also summarize the latest advances in nanobody molecular imaging tracers, emphasizing their preclinical and clinical use. In addition, we elaborate on nanobody-based near-infrared fluorescence (NIRF) imaging and image-guided surgery.
近年来,纳米抗体已成为分子成像的理想成像剂。分子纳米抗体成像将纳米抗体的特异性与最先进的分子成像方式(如正电子发射断层扫描 [PET])的灵敏度结合在一起。鉴于纳米抗体的修饰会改变其药代动力学(PK),因此将纳米抗体与放射性核素结合的工程策略决定了分子成像探针的有效性、可靠性和安全性。在这篇综述中,我们介绍了用于工程纳米抗体的偶联策略,包括随机偶联、Tc 三羰基化学、连接酶 A 介导的定点偶联、马来酰亚胺-半胱氨酸化学和点击化学。我们还总结了纳米抗体分子成像示踪剂的最新进展,强调了它们的临床前和临床应用。此外,我们详细阐述了基于纳米抗体的近红外荧光(NIRF)成像和图像引导手术。